GLP-1 Patient Support Program Design in Saudi Arabia & the GCC: A Practical Blueprint

What the programme says to patients must always be consistent with the approved prescribing information and the treating physician's advice.

1. Nurse-led onboarding. A trained nurse or pharmacist explains the plan, demonstrates the device and answers questions in the patient's language.
2. Injection confidence tools. Step-by-step videos, printed guides and practice devices reduce anxiety about self-administration.
3. Side-effect support pathway. Plain-language guidance on what is common, what to discuss with the team and when to seek urgent care, always routed through healthcare professionals.
4. Nutrition and activity education. Culturally relevant meal guidance that respects local cuisine and family dining, delivered by qualified dietitians. Include education on protein intake and resistance activity, to support overall health during weight change.
5. Behavioural and emotional support. Many patients carry years of shame or past setbacks; brief coaching and peer groups help.
6. Caregiver inclusion. Families shape daily choices. Provide guides for relatives and optional joint sessions.
7. Measurement and feedback loop. Collect patient-reported experience and share de-identified insights with the medical team.

Public interest in these therapies has attracted counterfeit, unregulated and mis-described products globally. A responsible PSP:

• Teaches patients to obtain medicines only through licensed pharmacies and prescribers
• Explains that therapy should be supervised by a physician
• Gives a clear channel for reporting side effects or suspected quality issues
• Corrects common online myths in neutral language

• Position the PSP as a service supporting appropriate use, not as a tool to drive prescribing.
• Keep education neutral and clinically accurate; avoid outcome promises.
• Obtain explicit, documented consent for communication and data use.
• Follow Saudi and UAE data-protection law and your pharmacovigilance obligations for adverse-event capture.
• Review everything with Medical, Regulatory, Legal and Data Protection teams before launch.

Use indicators that reflect engagement and persistence rather than weight outcomes alone: enrolment, onboarding completion, injection-training completion, contact rate with nurses, appointment attendance, programme satisfaction, persistence at agreed time points and reasons for discontinuation as reported by patients and clinicians.

Before writing a service blueprint, write one sentence that describes what a patient should be able to say about the programme six months in. For example: "I always knew who to call, I understood what was happening, and I never felt judged." Every service element, script and KPI should trace back to that promise. It also keeps the programme focused on support rather than on selling.

There is no single correct model. The right design depends on the health system, patient volumes, clinician preferences and regulations in each country.

Most successful programmes start with a pilot in a small number of institutions, measure what works and expand in phases.

The following timeline shows how the patient experience can be structured. It is an illustrative framework; every programme should be adapted to the product's approved information and the treating physician's plan.

Day 0 to 7: Welcome and confidence

• Enrolment with consent in the patient's language
• Introduction call or visit with a nurse or pharmacist
• Demonstration of the device with teach-back, where the patient shows how they will use it
• A written "what to expect" sheet and the programme contact details
• A follow-up call after the first dose to check understanding and answer questions

Week 2 to 8: Early adjustment

• Scheduled check-ins by phone or message
• Plain-language guidance on common experiences, such as digestive discomfort, and clear instructions to contact the clinician when concerned
• Dietitian session on meal patterns, hydration and food choices that fit local cuisine and family routines
• Reminders for follow-up appointments and dose-adjustment visits

Month 3 to 6: Building habits

• Behavioural coaching on routines, triggers and emotional eating
• Education on physical activity that suits the patient's current capacity
• Optional peer group sessions, in person or online, with strong privacy rules
• A caregiver session for family members

Month 6 to 12: Staying the course

• Review of progress from the patient's perspective, not only weight
• Support for plateaus, motivation dips and life events such as travel and Ramadan
• Conversations about long-term plans with the treating physician
• Structured exit or transition if a patient decides to stop, with a clear route back to care

Teach-back means asking patients to explain or demonstrate in their own words what they have just learned. It is more effective than asking "Do you understand?" because it reveals gaps without embarrassment. Use it for injection technique, storage, missed-dose guidance as given by the physician and when to call the care team. Record completion as a programme metric.

Weight change involves more than fat loss, and good programmes help patients think about overall health. Qualified dietitians can educate on balanced meals, adequate protein, hydration and fibre, practical strategies for reduced appetite and the role of regular strength and resistance activity suited to the individual. Provide culturally relevant examples, such as adapting traditional dishes, managing family gatherings and balancing meals at iftar and suhoor. All guidance should be reviewed by clinicians and personalised by the treating team, not delivered as one-size-fits-all rules.

People stop treatment for many reasons: side effects, cost or access, supply interruptions, loss of motivation, fear of long-term use, misinformation or life changes. A PSP should aim to understand those reasons respectfully, not to pressure patients to continue. Useful practices include:

• Asking open questions at every check-in about what is going well and what is difficult
• Recording reasons for discontinuation with the patient's consent and sharing anonymised themes with the medical team
• Offering a pathway to a physician review before a patient stops
• Ensuring that patients who stop know how to return to care and where to find reliable information

Digital tools extend capacity but must be simple. A practical set includes appointment and reminder messages, a bilingual video library on device use and nutrition, a secure channel to message a nurse, a caregiver view with limited, patient-approved information and a clinician dashboard with consented adherence signals. Avoid collecting more data than the programme needs, and make human help easy to reach from every screen.

PSP staff are often the first to hear about side effects or product concerns. Build a clear process that trains every team member to recognise and record adverse events and product-quality complaints, defines how and when reports are passed to the pharmacovigilance team, protects patient confidentiality and ensures patients are directed to appropriate medical care. This is both a legal obligation and a patient-safety essential.

Agree definitions and data sources with your medical, compliance and analytics teams before launch, and report in a way that respects patient privacy.

1. Days 1 to 30: Design. Map the patient journey, agree the service model, draft scripts and content, complete compliance review and data-protection assessment.
2. Days 31 to 60: Prepare. Recruit and train nurses or pharmacists, build the digital tools, brief partner clinics and test the process with a small group.
3. Days 61 to 90: Launch and learn. Enrol a pilot cohort, hold weekly review meetings, collect feedback from patients, caregivers and clinicians and refine the service.

After the pilot, expand to additional institutions and regions with a clear playbook.

• Programme seen as sales-driven: Keep education neutral, separate the PSP from commercial targets and train staff on boundaries.
• Inconsistent messages: Use approved scripts, regular retraining and a quality-monitoring process.
• Low engagement: Simplify the digital experience, offer multiple channels and make the first contact warm and useful.
• Data-privacy gaps: Map data flows, limit access and review vendor contracts.
• Staff burnout: Set realistic caseloads and provide clinical supervision and support.

What is a GLP-1 patient support program? A structured service that educates and supports patients who have been prescribed GLP-1 based therapy, covering device training, side-effect guidance, nutrition and long-term engagement.

Who should deliver a PSP? Trained nurses, pharmacists and dietitians, supported by digital tools, and aligned with the prescribing physician.

How can a PSP improve persistence? By anticipating barriers at each stage, providing timely human contact and keeping patients connected to their care team.

Is a PSP considered promotion? It must be designed as a patient-service programme with neutral education and robust governance; confirm the model with Regulatory and Legal.

Spectra Solutions MEA designs and delivers patient support programmes and digital health ecosystems across the GCC. Start the conversation.

• Saudi General Authority for Statistics: Health Determinants Statistics Publication 2023
• Saudi Ministry of Health: Obesity awareness
• WHO: Obesity and overweight
• Saudi clinical practice guideline for adult overweight and obesity

This article is for professional education and programme planning. It does not replace individual medical advice. Medical, Regulatory, Legal and native-language review is required before programme use.